Preview

Cardiovascular Therapy and Prevention

Advanced search

Apolipoprotein E gene polymorphisms: a relationship with the risk of coronary artery disease and the effectiveness of lipid-lowering therapy with rosuvastatin

https://doi.org/10.15829/1728-8800-2020-1-2297

Abstract

Aim. To analyze the associations of apolipoprotein E (APOE) gene polymorphisms (rs7412 and rs4420638) with the risk of coronary artery disease (CAD) and the effectiveness of lipid-lowering therapy with rosuvastatin.

Material and methods. The study involved the analysis of deoxyribonucleic acid samples and phenotypic data of 1700 unrelated individuals of Slavic origin, natives of Central Russia. A pharmacogenetic testing included 205 patients with CAD. Patients were prescribed rosuvastatin with determination of lipid levels and intima-media thickness (IMT) after 6 and 12 months of follow-up.

Results. Carriers of the minor T allele for rs7412 polymorphism of the APOE gene were characterized by a lower CAD risk and a higher baseline level of low-density lipoprotein cholesterol (LDL-C). Associations of this polymorphism depended on body mass index. An association with an increased CAD risk was typical for male carriers of the variant G allele for rs4420638 polymorphism of the APOE gene. When treating CAD patients with rosuvas-tatin, a more pronounced lipid-lowering effect on total cholesterol and LDL-C was characteristic of individuals homozygous for the minor T allele for rs7412 of the APOE gene after 1 month of therapy; decrease of the lipidlowering effect with respect to total cholesterol took place in carriers of the heterozygous A/G genotype of rs4420638 polymorphism of the APOE gene after 12 months of therapy. An association was found between the rs7412 polymorphism of the APOE gene and the changes of maximum IMT in CAD patients treated with rosuvastatin. It consisted of the absence of IMT regression in T allele carriers after 6 months of lipid-lowering therapy.

Conclusion. Polymorphisms of the APOE gene are associated with parameters of cholesterol metabolism, the risk of CAD and the effectiveness of lipid-lowering therapy with rosuvastatin.

About the Authors

M. I. Churilin
Kursk state medical university Ministry of health of Russia
Russian Federation
Kursk


S. I. Kononov
Kursk state medical university Ministry of health of Russia
Russian Federation
Kursk


Yu. V. Luneva
Kursk state medical university Ministry of health of Russia
Russian Federation
Kursk


Yu. E. Azarova
Kursk state medical university Ministry of health of Russia
Russian Federation
Kursk


E. Yu. Klesova
Kursk state medical university Ministry of health of Russia
Russian Federation
Kursk


A. V. Kharchenko
Kursk state medical university Ministry of health of Russia
Russian Federation
Kursk


S. N. Zhabin
Kursk state medical university Ministry of health of Russia
Russian Federation
Kursk


O. Yu. Bushueva
Kursk state medical university Ministry of health of Russia
Russian Federation
Kursk


S. V. Povetkin
Kursk state medical university Ministry of health of Russia
Russian Federation
Kursk


G. S. Mal
Kursk state medical university Ministry of health of Russia
Russian Federation
Kursk


M. A. Solodilova
Kursk state medical university Ministry of health of Russia
Russian Federation
Kursk


A. V. Polonikov
Kursk state medical university Ministry of health of Russia
Russian Federation
Kursk


V. A. Kazanov
Kursk regional clinical hospital
Russian Federation
Kursk


References

1. Webb TR, Erdmann J, Stirrups KE, et al. Wellcome Trust Case Control Consortium; MORGAM Investigators; Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators. Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease. JACC. 2017;69:823-36. doi:10.1016/j.jacc.2016.11.056.

2. Sacks FM. The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia. Curr Opin Lipidol. 2015;26(1):56-63. doi:10.1097/MOL.0000000000000146.

3. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507-37. doi:10.1146/annurev.genom.1.1.507.

4. Orekhov A, Novikov, N, Oishi Y, et al. Transcriptome analysis revealed inflammatory genes responsible for foam cell formation. Atherosclerosis. 2018;275:e116. doi:10.1016/j.atherosclerosis.2018.06.329.

5. Braesch-Andersen S, Paulie S, Smedman C, et al. ApoE production in human monocytes and its regulation by inflammatory cytokines. PLoS One. 2013;8(11):e79908. doi:10.1371/journal.pone.0079908.

6. Zhao QR, Lei YY, Li J, et al. Association between apolipoprotein E polymorphisms and premature coronary artery disease: a meta-analysis. Clinical Chemistry and Laboratory Medicine (CCLM). 2017;55(2):284-98. doi:10.1515/cclm-2016-0145.

7. Varga TV, Kurbasic A, Aine M, et al. Novel genetic loci associated with long-term deterioration in blood lipid concentrations and coronary artery disease in European adults. International journal of epidemiology. 2016;46(4):1211-22. doi:10.1093/ije/dyw245.

8. Zhu H, Xue H, Wang H, et al. The association of apolipoprotein E (APOE) gene polymorphisms with atherosclerosis susceptibility: a meta-analysis. Minerva Cardioangiologica. 2016;64(1):47-54 doi:10.1093/gerona/61.9.918.

9. Balakhonova TV, Tripoten' MI, Pogorelova OA. Ultrasonic methods for assessing the thickness of the intima-media complex of the arterial wall. SonoAce-Ultrasound. 2010;21:57- 63. (In Russ.) Балахонова Т.В., Трипотень М.И., Погорелова О.А. Ультразвуковые методы оценки толщины комплекса интима-медиа артериальной стенки. SonoAceUltrasound. 2010;21:57-63.

10. Alfonsi JE, Hegele RA, Gryn SE. Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine? Curr Atheroscler Rep. 2016;18(5):24. doi:10.1007/s11883-016-0573-6.

11. Dergunov AD. Apolipoprotein E genotype as a most significant predictor of lipid response at lipid-lowering therapy: mechanistic and clinical studies. Biomed. Pharmacother. 2011;65(8):597-603. doi:10.1016/j.biopha.2011.04.003.

12. Koopal C, van der Graaf Y, Asselbergs FW, et al. Influence of APOE-2 genotype on the relation between adiposity and plasma lipid levels in patients with vascular disease. Int J Obes (Lond). 2015;39(2):265-9. doi: 10.1038/ijo.2014.105.

13. Bertram L, McQueen MB, Mullin K, et al. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39(1):17-23. doi:10.1038/nq1934.

14. Hu M, Lui SS, Mak VW, et al. Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients. Pharmacogenet Genomics. 2010;20(10):634-7. doi:10.1097/FPC.0b013e32833de489.

15. Paternoster L, Martínez González NA, Lewis S, et al. Association between apolipoprotein E genotype and carotid intima-media thickness may suggest a specific effect on large artery atherothrombotic stroke. Stroke. 2008;39(1):48-54. doi:10.1161/STROKEAHA.107.488866.


Review

For citations:


Churilin M.I., Kononov S.I., Luneva Yu.V., Azarova Yu.E., Klesova E.Yu., Kharchenko A.V., Zhabin S.N., Bushueva O.Yu., Povetkin S.V., Mal G.S., Solodilova M.A., Polonikov A.V., Kazanov V.A. Apolipoprotein E gene polymorphisms: a relationship with the risk of coronary artery disease and the effectiveness of lipid-lowering therapy with rosuvastatin. Cardiovascular Therapy and Prevention. 2020;19(1):17-23. (In Russ.) https://doi.org/10.15829/1728-8800-2020-1-2297

Views: 1326


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)